China-developed inhalable vaccine for Covid-19 in late-stage trials


The inhaled vaccine being researched by CanSino is based on its Convidecia adenovirus vector vaccine for Covid-19. -CANSINOTECH.COM

BEIJING (China Daily/Asia News Network): An inhaled Covid-19 vaccine developed by Chinese firm CanSino Biologics has entered late-stage clinical trials, with data suggesting it is eligible to apply for emergency use in China, the company's chief scientist said.

Zhu Tao, a member of the Chinese People's Political Consultative Conference National Committee, said future Covid-19 vaccination may replace the "jab" with a "huff", and that the procedure is as simple as "sipping a cup of coffee".

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

China , inhaled , vaccine , Covid-10 , Omicron

   

Next In Aseanplus News

Spate of South Korean army deaths sparks safety concerns
Indonesia says former senior official a suspect in illegal tin mining probe
Emerging Markets - Philippine peso hits Nov 2022 lows, most Asian forex weak on a poor Tuesday (May 29)
Tencent’s marquee game generates over RM650mil in first week
Singapore turbulence flight investigation finds sharp altitude drop caused injuries
Hong Kong is more entrepreneurial, open and diverse than Singapore, finance chief Paul Chan tells US businesses
Four-year-old Hong Kong girl’s ‘rare’ cardiac arrest after receiving stitches sparks hospital probe
Copter tragedy: Full report to be released tomorrow, says Fahmi
Amendments to law needed for Cardiothoracic Surgery programme, says Fahmi
Seeking OECD membership, Indonesia reviews economic policies

Others Also Read